PT  - JOURNAL ARTICLE
AU  - IGLESIAS, LETICIA
AU  - VÍLCHEZ, ROCÍO
AU  - AGUÍN, SANTIAGO
AU  - GARCÍA, RAMÓN
AU  - PENA, CAROLINA
AU  - CARRAL, ALBERTO
AU  - HUIDOBRO, GERARDO
AU  - MOLINA, AUREA
AU  - GÓMEZ, JESÚS GARCÍA
AU  - COVELA, MARTA
AU  - COSTA, MARINHA
AU  - MEDINA, ANA
TI  - Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study
AID  - 10.21873/anticanres.17505
DP  - 2025 Mar 01
TA  - Anticancer Research
PG  - 1181--1191
VI  - 45
IP  - 3
4099  - http://ar.iiarjournals.org/content/45/3/1181.short
4100  - http://ar.iiarjournals.org/content/45/3/1181.full
SO  - Anticancer Res2025 Mar 01; 45
AB  - Background/Aim: Real-world evidence regarding the use of nivolumab in metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is limited. This study aimed to describe the clinical characteristics, outcomes, and safety of nivolumab in R/M SCCHN patients treated in routine clinical practice.Patients and Methods: This retrospective, observational study evaluated the efficacy/safety of nivolumab in 116 patients with R/M SCCHN treated at nine centers within the Galician Group of Head and Neck Cancer health network between 2017 and 2019.Results: Basal characteristics of patients included a median age of 60 years, ECOG performance status −2 (14%) and −3 (1%) and a first diagnosis of stage IV a/b/c (74%). Nivolumab was used as first line, second line, and third line therapy in 17%, 66%, and 17% of patients, respectively. After a median follow-up of 14 months (range=1-69 months), the median progression-free survival was 2.30 months (95%CI=1.45-3.14) and the median overall survival was 8.1 months (95%CI=5.93-10.23). Outcomes were better when nivolumab was administered earlier in treatment course. Grade 3/4 adverse events were observed in 21.27% of patients.Conclusion: These findings support the efficacy and safety of nivolumab in the real-world treatment of R/M SCCHN.